Aelix Therapeutics
Developing novel vaccines to cure HIV infection.
Launch date
Employees
Market cap
-
Enterprise valuation
CAD69—104m (Dealroom.co estimates Jan 2016.)
Company register number B66655598
Barcelona Catalonia (HQ & founding location)
Financials
Estimates*
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|
| Revenues | - | 1.6m | 1.8m | 1.1m | 1.3m |
| % growth | - | - | 13 % | (37 %) | 15 % |
| EBITDA | (<1m) | <1m | (1.6m) | (2.0m) | (2.5m) |
| % EBITDA margin | - | 3 % | (89 %) | (176 %) | (191 %) |
| Profit | (<1m) | (<1m) | (<1m) | (<1m) | (1.7m) |
| % profit margin | - | (1 %) | (6 %) | (64 %) | (128 %) |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Spinout | ||
€11.5m | Series A | ||
| N/A | €50.0k | Grant | |
| N/A | $2.2m | Late VC | |
| Total Funding | CAD20.3m | ||
Related Content
Recent News about Aelix Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.